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ABSTRACT
The effect of natural killer (NK) cell alloreactivity on the outcome of haploidentical hematopoietic stem cell
transplantation (HSCT), with or without in vitro T cell depletion, remains controversial. Killer immunoglob-
ulin-like receptors (KIRs) recognize human leukocyte antigen C and B epitopes on target cells, thereby
regulating NK cell activity. To examine the recovery of CD94:NKG2A and KIR (CD158a, CD158b, and
CD158e) expression by NK cells, we used flow cytometry to evaluate samples from 24 patients and their donors
before and in the year following unmanipulated HLA-haploidentical/mismatched blood and marrow trans-
plantation. Linear regression analysis demonstrated that NKG2A recovery was inversely correlated with
CD158b recovery in the year following transplant. The doses of T cell subgroups CD4 and CD8 were
inversely associated with CD158a and CD158e expression during the 2 months following transplantation.
Moreover, patients with grades II-IV acute graft-versus-host disease (aGVHD) or who received “high” doses
of T cells (>1.37  108/kg) showed delayed recovery of KIRs during the 2 months following transplantation.
Univariate analysis showed that patients with high CD94 expression by day 60 (>90%) or who received donors
with high CD94 expression (>80%) were associated with higher transplantation-related mortality (P  .006 or
.067, respectively) and poorer leukemia-free survival (P  .012 or .094, respectively). Thus, the occurrence of
aGVHD or the receipt of high doses of T cells in the allograft altered KIR reconstitution. Furthermore, high
levels of CD94 expression in donors or in recipients by day 60 might be a good predictor for poor prognosis.
© 2007 American Society for Blood and Marrow Transplantation
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Natural killer (NK) cells can discriminate “self”
rom “nonself” through their inhibitory natural killer
eceptor (NKR) expression. There are 2 types of inhib-
tory NKR. One type is the killer immunoglobulin-like
eceptor family (KIR), which includes inhibitory recep-
ors for the polymorphic determinants of HLA-A
KIR3DL2), HLA-B (KIR3DL1), and HLA-C o
34KIR2DL1, KIR2DL2, and KIR2DL3). In addition to
IRs, the NKG2A lectin-like receptor has speciﬁcity
or complexes of HLA-E and peptides derived from
he leader sequences of many, but not all, HLA-A,
LA-B, and HLA-C polypeptides [1].
The effect of KIR ligand incompatibility in the
raft-versus-host direction, which is associated with
K cell alloreactivity, on outcomes of haploidentical
r mismatched unrelated hematopoietic stem cell
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NKC Receptor Repertoires after Transplantation 735ransplantation (HSCT) remains controversial [2-10].
he observed inconsistent roles of KIR ligand mis-
atch seem to arise from different transplant proto-
ols with various extents of T cell depletion (TCD) in
itro or in vivo.
By evaluating the KIR expression of donor-de-
ived NK cells by day 100 after unmanipulated bone
arrow or TCD transplants, Cooley et al. [11] have
emonstrated that KIR reconstitution is altered by T
ells in the allograft and is associated with clinical
utcome, which may partially account for the different
oles of alloreactive NK cells in transplants. Shilling’s
revious report [12] showed that patients with idio-
yncratic low KIR recovery on NK cells suffered from
raft versus host disease (GVHD), early relapse, and
ther complications after HLA-matched HSCT.
guyen et al. [13] reported that the impaired cytotox-
city of low KIR- and high NKG2A-expressing NK
ells was associated with both patient death and re-
apse in TCD, haploidentical, KIR ligand-mismatched
SCT. Thus far, no report has evaluated the recon-
titution kinetics of KIRs or their associations with
linical outcomes after HLA-mismatched/haploiden-
ical HSCT without in vitro TCD. Recently, we
stablished a novel protocol that includes condi-
ioning with antithymocyte globulin (ATG) prior to
nmanipulated HLA-mismatched/haploidentical
lood and marrow transplantation. This protocol can
chieve comparable outcomes to HLA-identical sib-
ing transplantation [14,15]. Patients undergoing this
rotocol provide a unique model for analyzing KIR
econstitution in vivo under conditions of HLA-mis-
atch and high doses of T cells.
Therefore, the goal of this study was to examine KIR
ecovery on NK cells after HLA-mismatched/hap-
oidentical HSCT (with T cell repletion). Speciﬁcally,
e wished to assess any differences in KIR recovery that
ay affect the cytotoxicity and alloreactivity of NK cells
nd to compare results with those from studies of HLA-
atched HSCT or HLA-mismatched HSCT (with
CD), as reported by Shilling et al. [12] and Nguyen et
l. [13], respectively.
ETHODS
atients
Patients with hematologic malignancies suitable
or allo-HSCT who lacked HLA-identical related or
nrelated donors were candidates for the HLA-mis-
atched/haploidentical HSCT. Twenty-four patients
ith malignant hematologic disease who underwent
aploidentical allo-HSCT between April 2004 and
ecember 2004 were included in this study. All pa-
ients and their donors provided informed consent,
nd this study was approved by the institutional review
oard of Peking University Institute of Hematology. patient characteristics including age, sex, underlying
ematologic disorders, KIR ligand compatibility, the
ccurrence of aGVHD, and clinical outcomes are pre-
ented in Tables 1 and 2. Pretransplantation risk cat-
gories were low or high risk. High-risk diseases in-
luded acute myelogenous leukemia (AML) and acute
ymphoblastic leukemia (ALL) other than ﬁrst com-
lete remission (CR1); chronic myelogenous leukemia
ot in the ﬁrst chronic phase (CML not CP1); non-
odgkin’s lymphoma (NHL). Low-risk diseases were
LL CR1, AML CR1, and CML CP1.
onditioning Regimen, Mobilization, Collection
f Stem Cells, and Graft-versus-Host Disease
GVHD) Prophylaxis
All patients received myeloablative regimens. The
rugs administered before transplantation in the reg-
mens described below were cytosine arabinoside
Ara-C, 4 g/m2 on days10 and9), busulfan (Bu, 12
g/kg administered orally in 12 doses over 3 days, on
ays 8, 7, and 6), cyclophosphamide (Cy, 1.8
/m2 on days5 and4), simustine (Me-CCNU, 250
g/kg on day3), and ATG (10 mg/kg i.v., rabbit, on
ays 5 through 2; Sangstat) [14,15].
Donors received rhG-CSF (Filgrastim, 5 g/kg
aily for 5-6 days). On the fourth day, rhG-CSF-
rimed bone marrow cells (G-BM) were harvested.
he target total nucleated cell count was 3.0  108
median 3.6  108, range: 0.24-8.16  108) cells/kg
ecipient weight. On the ﬁfth and sixth days, rhG-
SF-mobilized peripheral blood progenitor cells
G-PBPCs) were collected. The target mononuclear
ell count was 3.0  108 (median 3.65  108, range:
.77-11.7  108) cells/kg recipient weight. The fresh
nd unmanipulated G-BM and G-PBPCs were in-
used into the recipients on the day of collection
14,15].
Prophylaxis for GVHD included cyclosporine A
CsA) and short-term methotrexate (MTX) with my-
ophenolate mofetil (MMF) [14,15]. CsA was started
.v. on day 9 at the dosage of 2.5 mg/kg. As soon as
he patient was able to take medication after engraft-
ent, CsA was switched to the oral formulation.
hole blood CsA concentration was monitored
eekly using a ﬂuorescence polarization immunoas-
ay, and the dosage was adjusted to achieve a blood
oncentration of 150-250 ng/mL. MMF was admin-
stered orally (0.5 g every 12 h) from day 9 before
ransplantation to day 30 after transplantation, then
.25 g MMF was given every 12 h for 1-2 months.
TX (15 mg/m2) was administered i.v. on day 1, and
0 mg/m2 MTX was given on days 3, 6, and 11 after
ransplantation. The diagnosis and grading of GVHD
as established according to published criteria [16].
Filgrastim (G-CSF, 5 g/kg per day) was given
ubcutaneously to all recipients from day 6 after trans-
lantation until the neutrophil count reached 0.5  109
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X.-Y. Zhao et al.736ells/L for 3 consecutive days [14,15]. Bone marrow
spiration and cytogenesis studies to assess engraft-
ent were performed 1, 2, and 3 months after trans-
lantation. HLA DNA typing and PCR-DNA ﬁnger-
rinting (short tandem repeat) were used for donor
himerism detection. For each patient, at least 2
ethods were used to conﬁrm donor chimerism
14,15].
ample Collection
Peripheral blood (10 mL) samples were drawn
rom donors and from patients before transplantation
nd at days 30, 60, 90,120, and 180 and at 1 year after
ransplantation. All samples were drawn within 4 days
f the speciﬁed days. Samples were available for 24
atients and their paired donors before transplanta-
ion, for 24 patients at days 30 and 60, for 20 patients
t day 120, for 16 patients at day 180, and for 12
atients at 1 year.
ntibodies and Flow Cytometry Analysis
Table 3 shows the combinations of monoclonal
ntibodies (mAbs) used in individual 4-color or
-color ﬂow cytometry assays to analyze KIR and
D94:NKG2A expression on NK cells or to analyze
able 1. Patient Characteristics
No. Age (y) Sex Diagnosis Donor
Don
Recipient
1 49 F CML Son HLA-C1,BW4
2 14 F CML Mother HLA-C1
3 33 M CML Sibling HLA-C1
4 41 M AML-M5 Sibling HLA-C2,BW4
5 22 M ALL Mother HLA-C1,C2,BW
6 16 M CML Mother HLA-C1,C2,BW
7 49 M AML-M4a Sibling HLA-C1,BW4
8 7 M ALL Father HLA-C1
9 16 F ALL Mother HLA-C1,BW4
10 8 M NHL-IIIB Mother HLA-C1
11 40 F CML Sibling HLA-C1,C2
12 13 M AML-M2 Mother HLA-C1,BW4
13 19 F NHL-IVA Mother HLA-C1,BW4
14 50 M AML-M5 Sibling HLA-C1,BW4
15 30 F CML Mother HLA-C1,BW4
16 41 M CML Sibling HLA-C1,C2,BW
17 28 F CML Sibling HLA-C1,BW4
18 10 F CML Mother HLA-C1,BW4
19 10 M AML-M2 Father HLA-C1
20 16 M ALL Mother HLA-C2,BW4
21 39 F CML Sibling HLA-C1,C2,BW
22 30 M CML Sibling HLA-C1
23 23 F CML Mother HLA-C1,C2
24 18 M AML Mother HLA-C1
indicates female; M, male;
GVH, donor-patients KIR ligand GVH direction mismatch; HVG
CR continuous complete remission; CML, chronic myelogenou
lymphoma; aGVHD, acute graft-versus-host disease; HVG, ho
Days after HSCT at last follow-up.he immunophenotype recovery of CD56 NK cells Bnd the NK cell subsets CD56dim and CD56bright. A
inimum of 100,000 nucleated, cell-gated events
ere acquired for each specimen. After gating on the
D3-CD56 lymphocyte (ie, NK cell), the KIR- or
D94:NKG2A-expressing populations were identi-
ed in the presence of an irrelevant isotype-matched
ontrol antibody to set the lower limit of the KIR- or
D94:NKG2A-positive gate, thereby excluding back-
round ﬂuorescence and receptor-negative cells. Ac-
uisition and analyses were performed with CellQuest
oftware (Beckton-Dickinson, San Jose, CA).
IR Ligand Typing and Grouping
HLA-A and -B were typed with serologic meth-
ds. HLA-C and -DRB1 alleles were typed with PCR-
SP (sequence-speciﬁc primer) as per the manufactur-
r’s instructions (Pel-Freez Biological, Rogar, AR). The
LA-C cells were classiﬁed into 2 groups: group 1
HLA-C1; including the HLA-Cw1, 3, 7, 8, 13, and 14
lleles) and group 2 (HLA-C2; including the HLA-
w2, 4, 5, 6, 12, 15, 17, and 18 alleles) [17]. CD158a
KIR2DL1/2DS1) was speciﬁc for HLA-C1, CD158b
KIR2DL2/2DL3/2DS2) was speciﬁc for HLA-C2,
nd CD158e (KIR3DL1) was speciﬁc for the HLA-B
llotypes expressing the serologic Bw4 epitope (HLA-
ient KIR Ligand#
aGVHD Outcome (Days*)Donor Mismatch
LA-C1 HVG () alive and CCR (770)
LA-C1 () II Relapse (370)
LA-C1 () () Dead, TRM (290)
LA-C1,C2,BW4 GVH IV Dead, TRM (90)
LA-C1,C2,BW4 () II alive and CCR (740)
LA-C1,C2 HVG () alive and CCR (733)
LA-C1 HVG III alive and CCR (724)
LA-C1,C2 GVH II Relapse (330)
LA-C1,BW4 () () alive and CCR (700)
LA-C1 () () Dead, TRM (60)
LA-C1,C2 () () alive and CCR (680)
LA-C1,BW4 () IV alive and CCR (567)
LA-C1,BW4 () () Dead, TRM (270)
LA-C1,BW4 () () Dead, TRM (200)
LA-C1,BW4 () II alive and CCR (605)
LA-C1,C2,BW4 () () alive and CCR (594)
LA-C1 HVG II Dead, TRM (355)
LA-C1,BW4 () II alive and CCR (560)
LA-C1,BW4 GVH II alive and CCR (546)
LA-C2,BW4 () () alive and CCR (531)
LA-C1,C2,BW4 () II alive and CCR (495)
LA-C1 () II alive and CCR (520)
LA-C1 HVG II alive and CCR (509)
LA-C1 () () alive and CCR (500)
r-patients KIR ligand HVG direction mismatch;
mia; AML, acute myelogenous leukemia; NHL, non-Hodgkin’s
s graft; TRM, transplant-related mortality.or-Pat
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NKC Receptor Repertoires after Transplantation 737tatistical Analysis
Data as of June 1, 2006, were analyzed. The cal-
ulations were carried out with SPSS statistical soft-
are. The nonparametric Wilcoxon test was used to
ompare the distributions of KIR and CD94:NKG2A
xpression levels. To test the differences in levels
etween donors and recipients paired after transplan-
ation, a Wilcoxon signed rank test was used. A
-sided Mann-Whitney U test was applied to compare
ifferences in KIR expression between the 2 catego-
ies of patients. Leukemia-free survival (LFS) was es-
imated using Kaplan-Meier methods. The probabil-
ties of relapse, transplant-related mortality (TRM),
nd grades II-IV acute GVHD (aGVHD) were calcu-
ated as cumulative incidences to adjust the analysis for
able 2. Patient Characteristics of the “High” and “Low” CD94 Expr
Group A G
12
edian patient age, years (range) 23 (8-50) 28
edian donor age, years (range) 42 (26-58) 39
atent sex, male, n (%) 6 (50%) 8
iagnosis
AML, n (%) 5 (42%) 1
ALL, n (%) 1 (8%) 3
CML, n (%) 4 (33%) 8
NHL, n (%) 2 (17%) 0
retransplantation risk categories*
High risk, n (%) 5 (51.7%) 4
umbers of Patient/donor HLA
incompatibility (HLA-A, -B, -DR)
1 locus, n (%) 2 (17%) 3
2 loci, n (%) 6 (50%) 5
3 loci, n (%) 4 (33%) 4
atient/donor KIR ligand
Match, n (%) 9 (75%) 7
HVG mismatch, n (%) 2 (17%) 3
GVH mismatch, n (%) 1 (8%) 2
II-IV aGVHD, n (%) 7 (58%) 6
cGVHD, n (%) 5/10 (50%) 7/12
edian (range)
CD34 infused,106/kg 2.39 (1.07-5.97) 2.38
CD3 infused,108/kg 1.90 (0.44-5.79) 1.5
he median expression of CD94 on NK cells in donors was 80% and t
group B according to greater than or lower than the median C
D based on greater than or lower than the median CD94 expre
ML indicates acute myelogenous leukemia; CML, chronic myelogen
CP, chronic phase; NHL, non-Hodgkin’s lymphoma; aGVHD, a
Pretransplantation risk categories were low or high risk. High-risk
Low-risk diseases were ALL CR1, AML CR1, and CML CP1.
able 3. Combinations of Fluorochrome-Labeled Monoclonal Antibodies
FITC-Ab
D158a/CD158b CD158a*
D158e CD158e*
D94:NKG2A CD94*
K subset CD16
From PharMingen (San Diego, CA).
From Beckman-Coulter-Immunotech (Brea, CA). The others were fromompeting risks. Log-rank test statistics were used to
valuate the univariate effects of “high” CD94 expres-
ion on outcome. Linear regression analysis was per-
ormed to examine the relationship between 2 contin-
ous measures of the expression of 2 proteins, or
etween the infused dose of T cell subgroups and the
arly recovery of KIRs. P  .05 was considered sta-
istically signiﬁcant.
ESULTS
linical Outcomes
Engraftment and complete donor chimerism after
ransplantation were achieved by all patients. As of
roups
P Value Group C Group D P Value
12 12
NS 28 (8-50) 20 (7-54) NS
NS 41 (26-58) 41 (35-43) NS
NS 7 (58%) 7 (58%) NS
0.044 0.044
5 (42%) 1 (8%)
1 (8%) 3 (25%)
4 (33%) 8 (67%)
2 (17%) 0 (0%)
NS NS
) 6 (50%) 3 (25%)
NS NS
2 (17%) 2 (17%)
7 (58%) 5 (42%)
3 (25%) 5 (42%)
NS NS
10 (83%) 6 (50%)
1 (8%) 4 (33%)
1 (8%) 2 (17%)
NS 7 (58%) 6 (50%) NS
NS 6/10 (60%) 6/12 (50%) NS
.58) NS 2.07 (1.07-5.97) 3.0 (1.45-5.58) NS
.87) NS 1.48 (0.44-3.19) 1.79 (1.18-5.79) NS
atients by day 60 were 90%. Patients were classiﬁed into group A and
pression of their donors, or were divided into group C and group
f patients by day 60.
kemia; ALL, acute lymphoblastic leukemia; CR, complete remission;
ft-versus-host disease; KIR, killer immunoglobulin-like receptors.
s included AML and ALL other than CR1; CML not CP1; NHL.
Used for Immunophenotyping
Ab PerCP-Ab APC-Ab
58b* CD3 CD56
CD3 CD56
2A† CD3 CD56
6 CD45 CD3ession G
roup B
12
(7-54)
(20-50)
(67%)
(8%)
(25%)
(67%)
(0%)
(33.3%
(25%)
(42%)
(33%)
(58%)
(25%)
(17%)
(50%)
(58%)
(1.45-5
(1.00-2
hat in p
D94 ex
ssion o
ous leu
cute gra
disease(mAb)
PE-
CD1
NKG
CD5Becton-Dickinson (San Jose, CA).
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X.-Y. Zhao et al.738une 1, 2006, 16 of the 24 patients survived without
eukemia, 6 patients died of TRM, and 2 patients
elapsed on day 370 and 330 after HSCT, respec-
ively.
econstitution Kinetics of CD94:NKG2A and KIR
CD158a, CD158b, CD158e) Expression by NK
ells after Transplantation
The quantitative evaluation of CD94:NKG2A
nd KIR expression on the surface of circulating
K cells after unmanipulated HLA-mismatched/
aploidentical blood and marrow transplantation
as performed by ﬂow cytometry in a series of 24
atients and their paired donors. Because the oc-
urrence of aGVHD and its therapy may affect
mmune recovery, only the 7 patients who survived
ithout leukemia and were exempt from grades
I-IV aGVHD were considered suitable for evalua-
ion of the reconstitution kinetics of CD94:NKG2A
nd KIRs on NK cells.
As shown in Figure 1A and B, the expression of
D94 and NKG2A on NK cells in recipients be-
ame signiﬁcantly higher than donor levels on day
0 after HSCT (P  .043 and .018, respectively),
hen sequentially decreased from day 60 to 1 year.
he levels of CD94 expression on NK cells by day
0 after transplantation were not signiﬁcantly dif-
erent than donor levels (P  .128; Figure 1A). In
ontrast, the levels of NKG2A expression on NK
ells at 1 year were still higher than donor values
P  .043; Figure 1B). Although the expression of
igure 1. Reconstitution kinetics of CD94:NKG2A and KIR express
anges, and extreme values of the expression of CD94 (A), NKG2A
sterisks () represent P  .05 compared with the expression levels of thell KIRs (CD158a, CD158b, and CD158e) after
ransplantation was equal to the donor levels (P 
1), the reconstitution kinetics of CD158a and
D158b expression were different from those of
D158e. The expression of CD158a and CD158b
iminished by day 30 after HSCT in patients (P 
398 and .398, respectively), and then sequentially
ncreased from day 60 to 1 year after HSCT (P  .1;
igure 1C and D). However, the reconstitution
inetics of CD158e expression on NK cells resem-
led those of CD94 or NKG2A expression, increas-
ng ﬁrst from day 30 to 60 (P  .310 and .499), and
hen sequentially decreasing from day 120 to 1 year
fter HSCT (P  .1; Figure 1E).
KG2A Expression Was Inversely Correlated with
D158b Expression after Transplantation
At day 30, a signiﬁcant inverse correlation be-
ween the expression of NKG2A and total HLA-C-
inding KIR (CD158a and CD158b) expression, in
articular CD158b expression, was found only in
atients with grades 0-I aGVHD (n  11; Figure
A). However, at the rest individual time points
fter transplantation (days 60, 120, 180, and 1 year,
espectively; Figure 2B-E), the expression of
KG2A was inversely correlated with that of
D158b in all observed patients (n  24, 20, 16,
nd 12, respectively). No correlation between
KG2A and CD158a or CD158e expression was
ound before or after transplantation.
NK cells after transplantation. The median, 25% to 75% percentile
KIRs on NK cells (C-E) were shown in the box plot (n  7). Theion by
(B), anddonors.
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NKC Receptor Repertoires after Transplantation 739cute GVHD Altered KIR Reconstitution
fter Transplantation
Among the 24 patients in the present study, 11
eveloped grades 0-I aGVHD and 13 developed
rades II-IV aGVHD. CD94:NKG2A reconstitution
as little inﬂuenced by the occurrence of grades II-IV
GVHD or its therapy. KIR expression on NK cells
ad reached donor levels within 1 month in patients
ho were exempt from grades II-IV aGVHD, or
ithin 4 months in patients with grades II-IV
GVHD (Figure 3). In patients of the grades II-IV
GVHD (n  13), expression on NK cells of CD158a
y day 30 and 60 (P  .012 and .050; Figure 3A) and
f CD158b by day 30 (P  .005; Figure 3B) was
igniﬁcantly lower than donor levels, but expression
n NK cells of CD158e (Figure 3C) was similar to
hat of the donors. Furthermore, CD158b expression
igure 2. NKG2A expression was inversely correlated with CD
KG2A expression and CD158b expression were shown in patient
y day 120 (n  20) (C), by day 180 (n  16) (D), and by 1 year (
igure 3. Acute GVHD altered KIR reconstitution after transplan
GVHD on CD158a (A), CD158b (B), and CD158e reconstitution (
n  13), ##P  .01 or #P  .05 compared with the expression levels ofn NK cells in patients with grades II-IV aGVHDwas
ower than in patients with grades 0-I aGVHD by day
0 (P  .018). KIR expression on NK cells in donors
f patients with grades II-IV aGVHD was similar to
hat in donors of patients with grades 0-I aGVHD
n  11, data not shown).
oses of T Cell Subgroups Infused Were Inversely
orrelated with the Levels of CD158a or CD158e
xpression after Transplantation
Linear regression analysis demonstrated a signiﬁ-
ant inverse correlation between the dose of CD4
cells infused and CD158a expression at days 30 and
0 (  0.517, P  .014, n  24; Figure 4A;  
0.492, P  .024, n  24; Figure 4B; respectively). A
igniﬁcant inverse correlation between dose of CD8
cells infused and CD158e expression at days 30 and
xpression after transplantation. The inverse correlation between
ut II-IV aGVHD by day 30 (n  11) (A), by day 60 (n  24) (B),
) after transplantation (E).
Effect of grades 0 -I (open column) versus II-IV (closed column)
 .05 between patients with grades 0-I (n 11) and II-IV aGVHD158b e
s withotation.
C). *Pthe donors.
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X.-Y. Zhao et al.7400 (  0.540, P  .010, n  24; Figure 4C;  
0.472, P  .031, n  24; Figure 4D; respectively)
as also revealed. No correlation was found between
oses of T cell subgroups infused and CD158b ex-
ression in patients after transplantation.
The median dose of CD3 cells in allograft of the
4 patients was 1.37  108/kg. Patients were classiﬁed
nto “low” or “high” T cell groups based on whether
hey received less or more than the median CD3 cell
ose. In patients of the “high” T cell group (n  12),
xpression on NK cells of CD158a (P .021 and .075;
igure 4E) and of CD158b (P .004 and .026; Figure
F) by day 30 and 60 was signiﬁcantly lower than
onor levels, but CD158e expression in the “high”
roup patients was similar to that of the donors (Fig-
re 4G). In contrast, in patients of the “low” T cell
igure 4. Doses of T cell subgroups infused were inversely correlat
nverse correlation between the dose of CD4 T cells infused and C
he dose of CD8 T cells infused and CD158e expression at days
2) versus “low” (open column, n 12) dose of T cells on CD158a (
atients of the “high” and “low” T cell groups; ##P  .01or #P roup (n  12), CD158a and CD158b expression on aK cells was similar to the levels of the donors,
hereas CD158e expression was signiﬁcantly in-
reased compared with the expression levels of the
onors by day 30 and 60 (P  .033 and .037; Figure
G). Furthermore, in patients of the “high” T cell
roup, expression on NK cells of CD158a (P  .028
nd .029; Figure 4E) and of CD158e (P  .003 and
024; Figure 4G) was lower than in patients of the
low” T cell group by days 30 and 60, respectively.
IR expression on NK cells in donors of patients in
he “high” T cell group was similar to that in donors
f patients in the “low” T cell group (data not shown).
ncreased CD94 Expression Correlated
ith Poor Survival
Up to June 1, 2006, 16 patients were alive who were
the levels of CD158a or CD158e expression after transplantation.
expression at days 30 (n  24) and 60 (n  24) (A, B), or between
24) and 60 (n  24) (C, D). Effect of “high” (ﬁlled column, n 
158b (F), and CD158e recovery (G). **P .01or *P .05 between
mpared with the expression levels of the donors.ed with
D158a
30 (n 
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NKC Receptor Repertoires after Transplantation 741median of 580 days (range: 495-770 days). Data as of
une 1, 2006, were analyzed. As shown in Figure 5A,
he levels of CD94 expression on NK cells were sig-
iﬁcantly higher in patients after transplantation com-
ared with their donors. The levels of CD94 expres-
ion in donors of patients with TRM or relapse (n 
) were signiﬁcantly higher than in donors of patients
ho were alive with continuous complete remission
CCR, n  16) (P  .029; Figure 5A). By day 60, the
evels of CD94 expression were signiﬁcantly higher in
atients who subsequently died of TRM or relapse
n  8) than in patients alive with CCR (n  16) (P 
027; Figure 5A). The median expression of CD94 on
K cells in donors was 80%, and that in patients by
ay 60 were 90%. To evaluate the predictive role of
D94 expression for LFS, patients were classiﬁed into
roup A (n  12) and group B (n  12) according to
reater than or lower than the median CD94 expres-
ion of their donors, or were divided into group C
n  12) and group D (n  12) based on greater than
r lower than the median CD94 expression of patients
y day 60. “High” levels of CD94 expression in do-
ors (group A) or in patients by day 60 (group C) were
ssociated with a higher cumulative incidence of TRM
42.9% versus 9.1%, P  .067; Figure 5B; 50% versus
%, P  .006; Figure 5C) and a lower cumulative
ncidence of 2-year LFS (50% versus 83.3%, P .094;
igure 5D; 41.7% versus 91.7%, P .012; Figure 5E)
igure 5. Increased CD94 expression correlated with poor surviva
ied of TRM/relapse (A) (ﬁlled column, n 8) versus those patients
roups. Cumulative incidence estimates of TRM for patients of gro
C) and group D (n  12); Kaplan-Meier survival estimates LFS for p
E). *P  .05 between the black and white column group. #P  .05 compared with “low” levels of CD94 expression in 0onors (group B) or in patients by day 60 (group D),
espectively. There were no differences in the cumu-
ative incidence of relapse between group A and group
(12.5% versus 8.3%, P  .856) or between group C
nd group D (14.3% versus 8.3%, P  .793). As
hown in Table 2, no substantial differences were
ound between group A and group B or between
roup C and group D except for the disease diagnosis
P  .044).
ymphocyte Reconstitution after Transplantation
To assess whether KIR reconstitution patterns re-
ected underlying differences in hematopoietic recov-
ry, the rates of lymphocyte reconstitution in white
lood cells (WBC) were analyzed by evaluating the
ount and proportions of total lymphocytes, total T
ells, and total NK cells (with NK subpopulations
D56dim and CD56bight). There were no signiﬁcant
ifferences in the reconstitution rates between pa-
ients receiving “high” (n  12) versus “low” doses of
cells (n  12) or between patients of group A (n 
2) and group B (n  12), or between patients of
roup C (n  12) and group D (n  12) after trans-
lantation (data not shown). However, a signiﬁcantly
elayed recovery of the total NK cell proportion in
BC was observed in patients with grades II-IV
GVHD (n  13) compared to patients with grades
rent levels of CD94 expression on NK cells between patients that
ith CCR (open column, n 16), or between their respective donor
 12) (B) and group B (n  12), or for patients of group C (n12)
of group A and group B (D), or for patients of group C and group D
d with the expression levels of the donors.l. Diffe
alive w
up A (n
atients-I aGVHD (n  11) by day 30 after transplantation
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X.-Y. Zhao et al.742P  .030; Figure 6A). Accordingly, both the absolute
roportions and counts of KIR-, CD94-, or NKG2A-
ositive NK cells in WBC were signiﬁcantly reduced
n patients with grades II-IV aGVHD (P .05; Figure
B and C). There were no signiﬁcant differences in
he ratio of CD56dim to CD56bright cells from patients
ith grades II-IV aGVHD versus grades 0-I aGVHD
P  .893).
ISCUSSION
In agreement with previous studies [11-13,18], we
ound that CD94:NKG2A was the predominant NK
ell receptor in the early posttransplantation period,
ut CD94:NKG2A expression decreased as KIR ex-
ression by NK cells increased. The expression of
KG2A and HLA-C-binding KIRs (especially
D158b) was inversely correlated during reconstitu-
ion, suggesting that these 2 types of receptors share a
ommon purpose and some degree of coordination in
heir differential expression during NK cell develop-
ent. These data provide evidence that the potential
or NKR repertoire recovery is a genetically pro-
rammed process [19] after HLA-mismatched/hap-
oidentical HSCT (with T cell repletion), which is
imilar to what was observed for HLA-matched trans-
lant [12] and HLA-mismatched transplant with
CD [13]. The different recovery kinetics of HLA-
-binding KIRs (CD158a and CD158b) versus an
LA-Bw4-binding KIR (CD158e) were also con-
rmed [11], but the clinical signiﬁcance should be
xplored in the future.
The time for KIR reconstitution after different
ransplant protocols varies from 5 to 36 months, as
escribed by Shilling et al. [12] and Nguyen et al. [13].
n our transplantation setting, we observed that KIR
xpression on NK cells had already reached donor
evels within 1 month in patients who survived with-
ut leukemia and who were exempt from grades II-IV
igure 6. Acute GVHD altered NK reconstitution after transplan
GVHD on the absolute proportion in WBC (TNC%) of overall N
n the absolute number in WBC per microliter (Cells/l) of KIR
etween patients with grades 0-I (n  11) and II-IV aGVHD (n GVHD, and within 4 month in patients with grades dI-IV aGVHD, although T cells in the allograft might
elay KIR reconstitution as reported by Cooley et al.
11]. Therefore, the reconstitution kinetics of KIRs
fter using the present protocol could be quicker than
hose after HLA-mismatched transplant with TCD or
LA-matched related or unrelated transplant [12,13].
everal possible factors, including genetic incompati-
ility between donor and recipient as well as TCD or
he use of intensive conditioning with total body irra-
iation (TBI), may be responsible for different rates of
IR reconstitution [12,13,18,19]. Although not yet
etermined, we anticipate that the use of a mixture of
-BM and G-PBPCs in the graft might be a factor in
he accelerated KIR reconstitution observed in the
resent transplant protocol, in addition to the high
egree of HLA-mismatch.
The effects of aGVHD and T cells on the recov-
ry of KIRs were also explored in our transplantation
rotocol. As far as aGVHD is concerned, because of
he delayed recovery of CD158b in some patients by
ay 30, the inverse correlation between NKG2A and
D158b was only existed in the 11 patients without
rades II-IV aGVHD. This ﬁnding suggests that
GVHD or its therapy has a predominantly inhibitory
ffect on the recovery of HLA-C group 2-binding
IRs (CD158b, KIR2DL2/2DL3/2DS2). Moreover,
GVHD and its therapy also delayed the recovery of
he proportion of NK cells in WBC. The inverse
orrelation between T cell subpopulations and the
arly recovery of CD158a or CD158b provided direct
vidence that T cells in the allograft may have a
redominantly inhibitory effect on the recovery of
LA-C group 1-binding KIRs (CD158a, KIR2DL1/
DS1) and HLA-Bw4-binding KIRs (CD158e,
IR3DL1). However, the overall proportion and
ount of NK cells in WBC were less affected by
high” doses of T cells (data not shown). Thus, a
reliminary conclusion could be drawn that “high”
Effect of grades 0 -I (open column) versus II-IV (closed column)
(A), of KIR positive or CD94 (B): NKG2A positive NK cells; and
e or CD94:NKG2A positive NK cells (C). *P  .05 or **P  .01tation.
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NKC Receptor Repertoires after Transplantation 743uantity of NK cells, whereas aGVHD and its therapy
mpair both NK cell quality and quantity.
The NK cell population can be further divided
nto CD56bright and CD56dim subsets. These pheno-
ypes may reﬂect different stages in NK development
r distinct regulatory and cytolytic NK subpopula-
ions [20]. The ratio of CD56dim to CD56bright cells
as similar in patients with grades II-IV aGVHD
ersus grades 0-I aGVHD and in patients with “high”
oses of T cells versus “low” doses. These ﬁndings
uggest that reduced KIR expression on NK cells in
atients with grades II-IV aGVHD or in patients with
high” doses of T cells could not be attributed to an
ltered ratio of CD56dim to CD56bright cells.
Administration of ATG prior to transplantation
esults in donor TCD in vivo. However, in the context
f similar dose of ATG (10 mg/kg) in the 24 patients,
he in vivo TCD effects of ATG might be different
etween patients of the “high” and “low” T cell
roups. In light of Cooley’s data [11], T cells in the
llograft might affect NK cell function and KIR ex-
ression in vivo after unrelated HSCT. In the present
ata, KIR reconstitutions were delayed in patients of
he “high” T cell group instead of in patients of the
low” T cell group, suggesting that in vivo TCD
ffects of ATG were weakened in “high” T cell group.
ur retrospective analysis has demonstrated that KIR
igand mismatch showed deleterious effects on clinical
utcomes, especially in the “high” T cell group [7],
hich provides some evidence for this hypothesis.
We also showed for the ﬁrst time that “high”
D94 expression in donors and in patients by day 60
ere associated with higher TRM and poorer LFS.
he characteristics of patients with “high” versus
low” CD94 expression were similar, except for the
isease diagnosis (P  .044; Table 2). Moreover, the
ates of LFS among patients with different diagnoses
AML, CML, ALL, or NHL) were similar (data not
hown). Thus, the signiﬁcantly different clinical out-
omes cannot be explained by the different disease
iagnoses between groups. Borrego et al. [21] demon-
trated that the CD94 receptor can block CD69-
nitiated cytotoxic effects of NK cells. Therefore,
high” CD94 expression on NK cells might inhibit
he cytotoxic effects of NK cells, which may cause
igher TRM, resulting in poorer survival. On the
hole, the characteristics of patients in group A were
early the same as those in group C, and those in
roup B were almost equivalent to group D. There-
ore, we propose that CD94 expression levels in do-
ors may aid investigators in donor selection.
In summary, this is the ﬁrst study to describe the
econstitution kinetics of the NKR repertoire after
LA-haploidentical/mismatched T cell-replete
SCT. Our results suggest that the occurrence of
GVHD or the receipt of a high dose of T cells in the
llograft alters KIR reconstitution. Furthermore, high 1evels of CD94 expression in donors or in recipients
y day 60 might be a good predictor for prognosis.
otential correlations between KIR reconstitution and
ther transplant-related complications, such as infec-
ion, are presently being investigated at our institute.
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